Hiv-tat exacerbates the actions of atazanavir, efavirenz, and ritonavir on cardiac ryanodine receptor (ryr2)

HIGHLIGHTS

• who: Fadhel A. Alomar et al. from the Department of Pharmacology and Toxicology, College of Clinical Pharmacy, Imam Abdulrahman Bin Faisal University, Dammam, Saudi Arabia have published the Article: HIV-Tat Exacerbates the Actions of Atazanavir, Efavirenz, and Ritonavir on Cardiac Ryanodine Receptor (RyR2), in the Journal: (JOURNAL) of 19/Dec/2022
• what: The authors show that the HIV protein Tat (HIVTat: 0-52 ng/mL) and therapeutic levels of the antiretroviral drugs atazanavir (ATV: 0-25 344 ng/mL) efavirenz (EFV: 0-11 376 ng/mL) and ritonavir (RTV: 0-25 956 ng/mL . . .
  

   

  

  If you want to have access to all the content you need to log in!

  Thanks :)

  Username or E-mail:

  If you don't have an account, you can create one here.